Lead Product(s): Denileukin Diftitox,Anti-PD-1 agent
Therapeutic Area: Oncology Product Name: E7777
Highest Development Status: Preclinical Product Type: Large molecule
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Combination of E7777 with an anti-PD-1 agent provided clear benefit both in terms of tumor growth control, and a highly significant improvement in overall survival.
Lead Product(s): XL102
Therapeutic Area: Oncology Product Name: XL102
Highest Development Status: Preclinical Product Type: Small molecule
Deal Size: $29.5 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement December 07, 2020
Exelixis has exercised exclusive option for Aurigene’s novel CDK7 inhibitor under the companies’ July 2019 agreement. Exelixis has now assumed responsibility for the future clinical development, commercialization, and global manufacturing of the compound now known as XL102.